SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.53), $0.01 better than the analyst estimate of ($1.54). Revenue for the quarter came in at $11.87 million versus the consensus estimate of $10.8 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.